Physician profile
Amanda Davis
NPI 1619413275
$9,459.70
in general payments reported to CMS, 2019-2025
32 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,772 · 2022: $1,830 · 2023: $1,741 · 2024: $2,356 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,834 · Education: $23.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,833.84 |
| Education | $23.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,251.01 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,117.22 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $963.48 | 2021-2025 | |
| Janssen Biotech, INC. | $696.98 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $597.10 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $591.99 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $516.26 | 2024-2025 | Voquezna |
| Genzyme Corporation | $468.86 | 2022-2025 | |
| Qol Medical, LLC | $386.21 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $384.15 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $349.92 | 2021-2025 | Gimoti |
| Gilead Sciences, INC. | $346.31 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $226.44 | 2021-2024 | Dificid |
| Pfizer INC. | $204.00 | 2023-2025 | |
| Redhill Biopharma INC. | $168.31 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $165.37 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $164.65 | 2024-2025 | Zenpep |
| Celgene Corporation | $163.77 | 2021-2024 | Zeposia |
| Lucid Diagnostics INC. | $112.75 | 2024 | |
| Lilly USA, LLC | $92.82 | 2024-2025 | Omvoh |
| Pharmacyclics LLC, An Abbvie Company | $75.88 | 2023 | Imbruvica, Epkinly |
| Intercept Pharmaceuticals, INC. | $65.85 | 2022-2025 | Ocaliva |
| Braintree Laboratories, INC. | $58.43 | 2021-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $48.69 | 2021-2023 | Clenpiq |
| Celltrion USA INC. | $46.94 | 2024 | Zymfentra |
| Organon LLC | $45.89 | 2024-2025 | Hadlima, Renflexis |
| Enterra Medical, INC. | $39.56 | 2024 | |
| Intra-Sana Laboratories | $36.28 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $27.94 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2022 | |
| Boston Scientific Corporation | $15.58 | 2022 | |
| Fresenius Kabi USA, LLC | $12.88 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.